Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

NCT03210714 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03210714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03210714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 5, 2018
Completion date
December 30, 2026
Enrollment
20 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, recurrent childhood ependymoma, recurrent childhood malignant germ cell tumor, recurrent childhood medulloblastoma, recurrent childhood non-hodgkin lymphoma, recurrent childhood osteosarcoma, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent hepatoblastoma, recurrent langerhans cell histiocytosis, recurrent malignant glioma, recurrent malignant solid neoplasm, recurrent neuroblastoma, recurrent primary central nervous system neoplasm, recurrent rhabdoid tumor, refractory childhood malignant germ cell tumor, refractory childhood osteosarcoma, refractory childhood rhabdomyosarcoma, refractory childhood soft tissue sarcoma, refractory ependymoma, refractory ewing sarcoma/peripheral primitive neuroectodermal tumor, refractory hepatoblastoma, refractory langerhans cell histiocytosis, refractory malignant glioma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory primary central nervous system neoplasm, refractory rhabdoid tumor, wilms tumor